老年人肌少症循环生物标志物的系统综述与荟萃分析
该系统综述与荟萃分析纳入26项观察性研究,比较社区居住的60岁以上肌少症与非肌少症老年人的循环生物标志物。
要点
- 肌少症老年人GDF-15水平显著升高,IGF-1水平显著降低。
- 其他循环生物标志物在肌少症与非肌少症组间无显著差异。
- IGF-1和GDF-15可能是肌少症的潜在生物标志物,需纵向研究验证。
核心结论
- 升高的循环IGF-1和程度较小的GDF-15可能是肌少症的 promising 生物标志物。
- 需要更大规模的纵向研究来解决异质性和因果性问题。
研究设计与样本
- 遵循PRISMA 2020指南,检索PubMed、Scopus、Web of Science和Cochrane Library从建库至2025年6月。
- 纳入26项观察性研究,共1345名肌少症成人(48.3%女性,平均年龄67.9-88.1岁),对照组为非肌少症成人。
- 纳入标准为60岁以上无主要合并症的成人,肌少症由既定共识定义。
- 使用随机效应模型计算标准化均数差(SMD),通过I2和meta回归评估异质性,Egger检验评估发表偏倚。
主要发现
- 肌少症成人GDF-15升高(k=5,SMD 0.26,95%CI 0.03-0.50,I2=64%,p=0.03)。
- 其他循环生物标志物在组间无显著差异。
关键数值与推荐
- GDF-15:k=5,SMD 0.26,95%CI 0.03-0.50,I2=64%,p=0.03。
- 其他生物标志物(activin A、follistatin、myostatin、生长激素、游离和总睾酮)组间无显著差异。
临床怎么用
- 在老年肌少症评估中可考虑检测循环GDF-15和IGF-1水平作为辅助生物标志物。
- 目前证据尚不足以将GDF-15或IGF-1作为肌少症的独立诊断工具,需结合临床评估。
局限性
- 纳入研究存在异质性(GDF-15的I2=64%)。
- 仅纳入观察性研究,无法推断因果关系。
- 需要更大规模的纵向研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia, the age-related loss of muscle mass and strength, poses a significant health and economic burden. This systematic review and meta-analysis evaluates circulating biomarkers (activin A, follistatin, growth differentiation factor (GDF-15), myostatin, growth hormone, insulin growth factor-1 (IGF-1), free and total testosterone) that may be associated with sarcopenia in community-dwelling older adults. METHODS: Following PRISMA 2020 guidelines, we searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to June 2025. Studies included adults without major comorbidities aged >60 years with sarcopenia defined by established consensus. Standardized mean differences (SMDs) were calculated using a random-effects model. Heterogeneity was assessed via I2 and meta-regressions, while Egger's test was employed for publication bias. RESULTS: From 3488 records, 26 observational studies were included (n = 1345 adults with sarcopenia, 48.3% females, mean age 67.9-88.1 years). Adults with sarcopenia showed elevated GDF-15 (k = 5, SMD: 0.26, 95% confidence interval (95% CI), 0.03 to 0.50, I2 = 64%, p = .03) and reduced IGF-1 (k = 11, SMD: -0.40, 95% CI, -0.54 to -0.27, I2 = 36%, p < .01) compared to controls without sarcopenia. No significant differences were found between groups for the other circulating biomarkers. CONCLUSIONS: Elevated circulating IGF-1 and, to a lesser extent, GDF-15, may be promising biomarkers for sarcopenia. Larger, longitudinal studies are needed to address heterogeneity and causality.
引用
- Prokopidis K, Deane CS, Baoubbou Z, et al. Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2026. PMID: 42202210. doi:10.1093/gerona/glag140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。